in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Ranbaxy receives FDA notice of possible API plant violations
5:41 AM MST | January 13, 2014 | Natasha Alperowicz
Ranbaxy Laboratories (Gurgaon, India), India’s largest drugs maker and member of the Daiichi Sankyo Group (Tokyo), has been notified by the US Food and Drug Administration (FDA) that a recent inspection found possible violations at Ranbaxy’s APIs plant at Toansa, India. Ranbaxy says that on 11 January it received Form 483 with certain observations following the recent US FDA inspection at the plant. Ranbaxy “is assessing the observations, and will respond to the FDA in accordance with the agency's procedure to resolve the concerns at the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee